Skip to main content

VolitionRx Receives $700K in Funding From Regional Government

NEW YORK (GenomeWeb) — VolitionRx announced today that it has received $700,000 in non-dilutive funding from the government of the Wallonia region of Belgium where the company is headquartered.

According to VolitionRx, roughly $200,000 of the funding is repayable in annual installments over 12 years, beginning in 2020. Additionally, an undisclosed percentage of the company's revenue may be payable to the Walloon regional government over the same period.

VolitionRx said that it intends to use the funds to continue R&D efforts for cancer diagnostics based on its Nucleosomics nucleosome analysis technology.

In late 2017, the firm said that it had received $1.5 million in non-dilutive funding from Sofinex and the Walloon government. It said it has received a total of $3.7 million in non-dilutive funding from local agencies to date.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.